The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...

Quality scores dipped during the COVID-19 pandemic, but are now at or above 2019 levels in areas such as diabetes and asthma management.

Biocon said that its wholly owned subsidiary, Biocon Biologics announced strategic collaboration agreement with Civica, Inc. to expand access, affordability of Insulin Aspart in the United States.

Manufacturers always print the insulation printing dates clearly on the product. This is the date that the insulin pen or ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Surging Demand for Insulin Dosing Precision: With 35 million insulin-dependent patients worldwide, healthcare systems are prioritizing smart syringes equipped with real-time monitoring. Mobile health ...

The "Insulin Pens Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.The report is built to visualize ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...

Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the ...